Prof. Paquet-Durand is Assistant Professor at the Institute for Ophthalmic Research, University of Tübingen and Chief Scientific Officer of Mireca Medicines GmbH.
His talk will be on: “Targeting cGMP-signalling in inherited retinal degeneration: from basic research to clinical translation, Founding of Drugsford”
This talk is hosted by the Bayer Graduate Program of Pharmacology and Experimental Therapeutics.
He has been the group leader for the Cell Death Mechanisms group at the Institute for Ophthalmic Research, University of Tübingen since 2009. From 2012-2016, he was coordinator and project leader for the DRUGSFORD project, www.drugsford.eu. This project, funded by the European Union 7th framework program, pursued the idea of using cyclic nucleotide analogs to combat inherited retinal degeneration. As Chief Scientific Officer of Mireca Medicines GmbH, a Tübingen based pre-clinical stage bio-pharmaceutical company focusing on research and development of treatments for rare, neuro-degenerative eye diseases, he aims to translate research data generated in the EU-funded DRUGSFORD project into treatments for patients, with all original consortium partners as shareholders.